Currently, the biomarkers that have been identified for potential targeted therapy treatments for lung cancer are: EGFR, ALK, KRAS, MET, HER2, ROS1, BRAF, RET, NTRK1, PID3CA, MED1, VEGFR2, HER3, and IGF-1R. Of those, so far only EGFR, ALK+, and ROS1 have treatments approved by the FDA. However, there are many more treatments that are in clinical trials.
In this section of the Hope With Answers℠ series, learn more about the KRAS biomarker and the most current information available regarding approved treatments.
Hope With Answers Video Series: Biomarker KRAS
Discover in-depth information about the KRAS biomarker and lung cancer. Patient advocate Terri Conneran asks Dr. David Carbone from The Ohio State University James Cancer about the KRAS biomarker in lung cancer. KRAS is present in about 25% of lung cancers, but, until recently there have not been effective targeted treatments for this biomarker. Learn what new treatments are currently in trials and expected to be available for patients soon. Get the latest information on tests and treatment possibilities for this biomarker.